|AHFS/Drugs.com||Micromedex Detailed Consumer Information|
|Excretion||Fecal and renal|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||212.66 g/mol|
Magaldrat was first synthesized by the German chemist Gunther Hallmann and patented on February 2, 1960, by Byk Gulden Lomberg Chemische Fabrik (Germany). In 1983, the active substance was registered as the original drug Riopan.
Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly by gastric acid into Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.
Interactions and adverse reactions
Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.
This article needs additional citations for verification. (September 2014)
- US patent 2923660, Hallmann G, "Process for the preparation of magnesium aluminate hydrate, and therapeutic agents so produced", issued 1960-02-02, assigned to Byk Gulden Lomberg Chem. Fab.
- Fachinfo Riopan Magen Tabletten, Stand Dezember 2014.
- Laurence BL. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.